Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks after 26 mos & 50% maintained complete remission without GC. Other half had sinonasal Sxs Rx w/ increased MEP dose orlocal therapy. https://t.co/M4Gp52QdwQ https://t.co/zb13fuKhpH
Links:
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polya…
https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheu…
Apr-21-2025
